These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31219366)

  • 41. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
    Smith JA; Kalimullah FA; Erickson CP; Peng LS
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.
    den Hollander JG; Rijnders BJ; van Doornum GJ; van der Ende ME
    AIDS; 2005 Mar; 19(6):639-40. PubMed ID: 15802989
    [No Abstract]   [Full Text] [Related]  

  • 43. Quality of life with pegylated interferon therapy for hepatitis C.
    Brown RS
    Hepatology; 2002 Sep; 36(3):767-8; author reply 768. PubMed ID: 12198677
    [No Abstract]   [Full Text] [Related]  

  • 44. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
    Wiegand J; Maasoumy B; Buggisch P; Buslau A; Schiefke I; Berg T; Wedemeyer H; Sarrazin C; Hinrichsen H
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1342-4. PubMed ID: 24803258
    [No Abstract]   [Full Text] [Related]  

  • 45. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E
    Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
    [No Abstract]   [Full Text] [Related]  

  • 46. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peginterferon-alpha(2b) and ribavirin.
    Ahn J; Flamm S
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):17-25. PubMed ID: 15482168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythema Annulare Centrifugum in the Era of Triple Therapy With Boceprevir Plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection.
    di Meo N; Stinco G; Fadel M; Errichetti E; Trevisan G
    J Cutan Med Surg; 2015; 19(3):203-4. PubMed ID: 26060126
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of hepatitic C virus infection after the French 2002 Consensus Conference].
    Cacoub P
    Rev Med Interne; 2002 Nov; 23(11):889-92. PubMed ID: 12481388
    [No Abstract]   [Full Text] [Related]  

  • 52. Interferon for hepatitis C patients with psychiatric disorders.
    Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
    [No Abstract]   [Full Text] [Related]  

  • 53. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 54. [Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
    MMW Fortschr Med; 2003 Jun; 145(26):52-3. PubMed ID: 12916339
    [No Abstract]   [Full Text] [Related]  

  • 55. A view to natural killer cells in hepatitis C.
    Shoukry NH; Pelletier S; Chang KM
    Gastroenterology; 2011 Oct; 141(4):1144-8. PubMed ID: 21875586
    [No Abstract]   [Full Text] [Related]  

  • 56. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
    Hadziyannis SJ; Sevastianos V
    Aliment Pharmacol Ther; 2013 Feb; 37(4):491. PubMed ID: 23336678
    [No Abstract]   [Full Text] [Related]  

  • 57. Regression of low-grade non-Hodgkin's lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection.
    Mazzaro C; Spina M; Tirelli U
    J Clin Oncol; 2005 Jul; 23(19):4470-1; author reply 4471. PubMed ID: 15994165
    [No Abstract]   [Full Text] [Related]  

  • 58. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
    Wang LJ; Chen SW; Chen CK; Yen CL; Chang JJ; Lee TS; Liu CJ; Chen LW; Chien RN
    BMC Psychiatry; 2016 Nov; 16(1):424. PubMed ID: 27884134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
    Riley TR
    Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.